Skip to main content
Top
Published in: Trials 1/2016

Open Access 01-12-2016 | Study protocol

Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials

Authors: Joyce P. Samuel, Joshua A. Samuels, Lauren E. Brooks, Cynthia S. Bell, Claudia Pedroza, Donald A. Molony, Jon E. Tyson

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

Children are increasingly being diagnosed with primary hypertension. The absence of comparative effectiveness research of antihypertensive medications in children has contributed to considerable differences in prescribing practices among physicians treating children with primary hypertension. Even if parallel-group trials had established a best overall choice for most of these children, the best medication for an individual may differ from the best overall medication.

Methods/design

This project consists of a series of systematically administered n-of-1 trials among older children to verify the need for ongoing antihypertensive treatment and, if so, to identify the preferred single drug therapy from among the three major classes of drugs commonly used for primary hypertension (angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics). We will determine whether one of these is the preferred therapy for the great majority of patients. The “preferred” therapy is the drug which produces normal ambulatory blood pressure, with the greatest reduction in blood pressure without unacceptable side effects. We will recruit 50 patients from the Houston Pediatric and Adolescent Hypertension Program clinic. For each patient, the three drugs will be prescribed in random order and each drug will be taken for 2 weeks. The effectiveness of each therapy will be measured with 24-h ambulatory blood pressure monitoring, and tolerability will be assessed using a side effect questionnaire. Participants will rotate through treatment periods, repeating drugs and adjusting doses until the preferred therapy is identified. In assessing whether one of the medications is most effective for the majority of subjects, the primary outcome will be the percentage of participants for whom each drug is selected as the preferred therapy. We hypothesize that no drug will be selected for the great majority of the subjects, a finding that would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore whether patient characteristics predict which medication will be selected as a preferred drug.

Discussion

This study will help optimize care of participating patients and provide evidence regarding the usefulness of n-of-1 trials in identifying appropriate treatment for children with hypertension and potentially other disorders.

Trial registration

Clinicaltrials.gov NCT02412761 (registered 4/8/2015).
Literature
2.
go back to reference Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr. 2008;9(6):809–15. doi:10.1093/ejechocard/jen155.PubMedCrossRef Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlöf B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). Eur J Echocardiogr. 2008;9(6):809–15. doi:10.​1093/​ejechocard/​jen155.PubMedCrossRef
3.
go back to reference Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202. doi:10.1161/01.HYP.0000154082.72286.2a.PubMedCrossRef Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198–202. doi:10.​1161/​01.​HYP.​0000154082.​72286.​2a.PubMedCrossRef
4.
go back to reference Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension. The LIFE study. Am J Hypertens. 2012;25(10):1101–9. doi:10.1038/ajh.2012.86.PubMedCrossRef Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, et al. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension. The LIFE study. Am J Hypertens. 2012;25(10):1101–9. doi:10.​1038/​ajh.​2012.​86.PubMedCrossRef
5.
go back to reference Turnbull F. Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.PubMedCrossRef Turnbull F. Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35.PubMedCrossRef
6.
go back to reference SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64.CrossRef SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255–64.CrossRef
7.
go back to reference Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242(23):2562–71.CrossRef Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242(23):2562–71.CrossRef
8.
go back to reference Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213(7):1143–52.
10.
go back to reference National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.
19.
go back to reference Kravitz RL DN, the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I,, Gabler NB KH, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S). Design and implementation of N-of-1 trials: a user’s guide. Rockville, MD: Agency for Healthcare Research and Quality;2014. Kravitz RL DN, the DEcIDE Methods Center N-of-1 Guidance Panel (Duan N, Eslick I,, Gabler NB KH, Kravitz RL, Larson EB, Pace WD, Schmid CH, Sim I, Vohra S). Design and implementation of N-of-1 trials: a user’s guide. Rockville, MD: Agency for Healthcare Research and Quality;2014.
21.
go back to reference Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients’ preferences matter. BMJ. 2012;345, e6572.PubMedCrossRef Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients’ preferences matter. BMJ. 2012;345, e6572.PubMedCrossRef
22.
23.
go back to reference Greenfield S, Kaplan S, Ware Jr JE. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med. 1985;102(4):520–8.PubMedCrossRef Greenfield S, Kaplan S, Ware Jr JE. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med. 1985;102(4):520–8.PubMedCrossRef
24.
go back to reference Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988;139(6):497–503.PubMedPubMedCentral Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988;139(6):497–503.PubMedPubMedCentral
25.
go back to reference Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest. 1999;115(1):38–48.PubMedCrossRef Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest. 1999;115(1):38–48.PubMedCrossRef
29.
go back to reference Senior HE, Mitchell GK, Nikles J, Carmont SA, Schluter PJ, Currow DC, et al. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. BMC Palliat Care. 2013;12(1):17. doi:10.1186/1472-684X-12-17.PubMedPubMedCentralCrossRef Senior HE, Mitchell GK, Nikles J, Carmont SA, Schluter PJ, Currow DC, et al. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. BMC Palliat Care. 2013;12(1):17. doi:10.​1186/​1472-684X-12-17.PubMedPubMedCentralCrossRef
32.
go back to reference Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.PubMedCrossRef Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.PubMedCrossRef
36.
go back to reference Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61. doi:10.1161/01.HYP.0000150859.47929.8e.PubMedCrossRef Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61. doi:10.​1161/​01.​HYP.​0000150859.​47929.​8e.PubMedCrossRef
37.
go back to reference Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol. 1977;12(4):297–303.PubMedCrossRef Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol. 1977;12(4):297–303.PubMedCrossRef
39.
go back to reference Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007;22(5):695–701. doi:10.1007/s00467-006-0399-5.PubMedCrossRef Hogg RJ, Delucchi A, Sakihara G, Wells TG, Tenney F, Batisky DL, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol. 2007;22(5):695–701. doi:10.​1007/​s00467-006-0399-5.PubMedCrossRef
42.
go back to reference Barnes VA, Johnson MH, Dekkers JC, Treiber FA. Reproducibility of ambulatory blood pressure measures in African-American adolescents. Ethn Dis. 2002;12(4):S3-101-6.PubMedPubMedCentral Barnes VA, Johnson MH, Dekkers JC, Treiber FA. Reproducibility of ambulatory blood pressure measures in African-American adolescents. Ethn Dis. 2002;12(4):S3-101-6.PubMedPubMedCentral
44.
go back to reference Lurbe E, Redon J. Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens. 2002;15(2 Pt 2):69S–73S.PubMedCrossRef Lurbe E, Redon J. Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens. 2002;15(2 Pt 2):69S–73S.PubMedCrossRef
45.
go back to reference Stergiou GS, Alamara CV, Salgami EV, Vaindirlis IN, Dacou-Voutetakis C, Mountokalakis TD. Reproducibility of home and ambulatory blood pressure in children and adolescents. Blood Press Monit. 2005;10(3):143–7.PubMedCrossRef Stergiou GS, Alamara CV, Salgami EV, Vaindirlis IN, Dacou-Voutetakis C, Mountokalakis TD. Reproducibility of home and ambulatory blood pressure in children and adolescents. Blood Press Monit. 2005;10(3):143–7.PubMedCrossRef
47.
go back to reference Gorostidi M, Sarafidis PA, de la Sierra A, Segura J, de la Cruz JJ, Banegas JR, et al. Differences between office and 24-h blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62(2):285–94. doi:10.1053/j.ajkd.2013.03.025.PubMedCrossRef Gorostidi M, Sarafidis PA, de la Sierra A, Segura J, de la Cruz JJ, Banegas JR, et al. Differences between office and 24-h blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62(2):285–94. doi:10.​1053/​j.​ajkd.​2013.​03.​025.PubMedCrossRef
48.
go back to reference Parati G, Ravogli A, Mutti E, Santucciu C, Omboni S, Mancia G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs. J Hypertens Suppl. 1994;12(8):S9–15.PubMed Parati G, Ravogli A, Mutti E, Santucciu C, Omboni S, Mancia G. Ambulatory blood pressure monitoring in the evaluation of antihypertensive drugs. J Hypertens Suppl. 1994;12(8):S9–15.PubMed
49.
go back to reference Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94(2):181–7.PubMedCrossRef Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94(2):181–7.PubMedCrossRef
50.
go back to reference Neutel JM, Smith DH, Ram CV, Lefkowitz MP, Kazempour MK, Weber MA. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol. 1993;72(1):41–6.PubMedCrossRef Neutel JM, Smith DH, Ram CV, Lefkowitz MP, Kazempour MK, Weber MA. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol. 1993;72(1):41–6.PubMedCrossRef
51.
go back to reference Mansoor GA. Ambulatory blood pressure monitoring in clinical trials in adults and children. Am J Hypertens. 2002;15(2 Pt 2):38S–42S.PubMedCrossRef Mansoor GA. Ambulatory blood pressure monitoring in clinical trials in adults and children. Am J Hypertens. 2002;15(2 Pt 2):38S–42S.PubMedCrossRef
52.
go back to reference Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi:10.1016/j.jbi.2008.08.010.PubMedCrossRef Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi:10.​1016/​j.​jbi.​2008.​08.​010.PubMedCrossRef
53.
go back to reference Punja S, Eslick I, Duan N, Panel tDMCN-o-G. An Ethical Framework for N-of-1 Trials: Clinical Care, Quality Improvement, or Human Subjects Resarch? Rockville, MD: Agency for Healthcare Research and Quality; 2014. Contract No.: Chapter 2. Punja S, Eslick I, Duan N, Panel tDMCN-o-G. An Ethical Framework for N-of-1 Trials: Clinical Care, Quality Improvement, or Human Subjects Resarch? Rockville, MD: Agency for Healthcare Research and Quality; 2014. Contract No.: Chapter 2.
54.
go back to reference Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. The Hastings Center report. 2013;Spec No:S16-27. doi:10.1002/hast.134. Faden RR, Kass NE, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. The Hastings Center report. 2013;Spec No:S16-27. doi:10.​1002/​hast.​134.
55.
go back to reference Kass NE, Faden RR, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. The Hastings Center report. 2013;Spec No:S4-S15. doi:10.1002/hast.133. Kass NE, Faden RR, Goodman SN, Pronovost P, Tunis S, Beauchamp TL. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. The Hastings Center report. 2013;Spec No:S4-S15. doi:10.​1002/​hast.​133.
Metadata
Title
Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials
Authors
Joyce P. Samuel
Joshua A. Samuels
Lauren E. Brooks
Cynthia S. Bell
Claudia Pedroza
Donald A. Molony
Jon E. Tyson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-1142-y

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue